

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SBR Pharmaceuticals Corp.	11/07/2002
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Synta Pharmaceuticals Corp.
<b>Street Address:</b>	45 Hartwell Avenue
<b>City:</b>	Lexington
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02421
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	10655672
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)439-4170
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	6174394444
<b>Email:</b>	trademark@edwardsangell.com
<b>Correspondent Name:</b>	Mark D. Russett
<b>Address Line 1:</b>	Edwards & Angell, LLP
<b>Address Line 2:</b>	101 Federal Street
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02110
<b>NAME OF SUBMITTER:</b>	Mark D. Russett (Reg. No. 41,281)
<b>Total Attachments: 4</b> source=SBR Synta Assignment#page1.tif source=SBR Synta Assignment#page2.tif source=SBR Synta Assignment#page3.tif source=SBR Synta Assignment#page4.tif	

OP \$40.00 10655672

## PATENT ASSIGNMENT

This PATENT ASSIGNMENT is made as of November \_\_\_\_, 2002 by SBR Pharmaceuticals Corp., f/k/a Shionogi BioResearch Corp., a Delaware corporation with its principal place of business at 45 Hartwell Avenue, Lexington, MA 02421 ("Assignor").

### RECITALS

WHEREAS, Assignor is the beneficial owner of all rights, title and interests in certain United States patents and applications identified on Schedule A attached hereto (the "Patents");

WHEREAS Assignor has agreed to transfer certain of its assets and the intellectual property rights thereto, including, without limitation, the Patents, to Synta Pharmaceuticals Corp., a Delaware corporation, with its principal place of business at 45 Hartwell Avenue, Lexington, MA 02421 ("Assignee"); and

WHEREAS, Assignee desires to acquire all rights, title and interests in, to and under said Patents.

NOW, THEREFORE, for One Dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor:

1. Assignor hereby conveys, assigns, transfers and delivers absolutely to Assignee, its successors and assigns free from encumbrances, (i) all rights, title and interests throughout the world in, to and under the Patents, and the underlying inventions described therein and any United States or foreign reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof, and substitutes therefor, and all rights of priority under International Conventions, and all letters patent of the United States which have been or may be granted thereon and all foreign counterparts thereof, together with all rights and powers arising or accrued therefrom including, without limitation, the right to sue and recover damages and other remedies for future or past infringements of the Patents and to fully and entirely stand in the place of Assignor in all matters related thereto, and (ii) the right to apply for, prosecute and obtain patents or similar protection throughout the world in respect of the inventions claimed in the Patents including the right to claim priority therefrom to the intent that the grant of any patents or similar protection shall be in the name of and vest in the Assignee.

2. Assignor agrees to communicate to Assignee, its successors, legal representative and assigns, any facts known respecting the Patents and provide testimony in any legal proceedings, and to execute such additional documents as may be necessary to perfect Assignee's title in and to the Patents and all foreign counterparts thereof. In addition, Assignor hereby conveys, assigns, transfers and delivers to Assignee, its successors and assigns, all of its right, title and interest throughout the world in and to all lab notes, prototypes, product definition, market analysis, marketing studies, draft patent applications, any and all correspondence with the United States Patent and Trademark Office or any foreign patent office, trade secrets, nondisclosure agreements, invention agreements, noncompete agreements and any other document recording the secret knowledge of Assignor relating to the Patents.

3. Assignor hereby requests the Commissioner of Patents and Trademarks (the "Commissioner") to record this Patent Assignment to Assignee. Assignor hereby further requests the Commissioner to issue any and all letters patent of the United States or derived from the Patents to Assignee as assignee of the entire interest. Assignor hereby covenants that the Commissioner has full right to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreements inconsistent herewith.

This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. This Agreement may not be supplemented, altered or modified in any manner except by a writing signed by both parties hereto. The failure of either party to enforce any terms or provisions of this Assignment will not waive any rights under such terms and provisions. This Agreement may be executed by facsimile signature and in counterparts, each of which will be an original and all of which when taken together will constitute one and the same Instrument.

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment to be executed as of the day and year first written above.

SBR PHARMACEUTICALS CORP.

By: *AM Ono*  
Name: Dr. Mitsunori Ono  
Title: President

THE COMMONWEALTH OF MASSACHUSETTS


County of Middlesex

On this the 7th day of November, 2002 before me personally appeared Dr. Mitsunori Ono and Dr. Safi R. Bahcall to me personally known, and known to me to be the person who signed the foregoing assignment, and acknowledged the signing of same as his free act and deed.

*Xu Ling Hu*  
Notary Public  
My commission expires 04/24/2009

Acknowledged and accepted:

SYNTA PHARMACEUTICALS CORP.



By: *Safi R. Bahcall*  
Name: Dr. Safi R. Bahcall  
Title: CEO

SCHEDULE A  
TO  
PATENT ASSIGNMENT

<u>Title</u>	<u>US Application Number/Filing Date</u>	<u>Issued Patent Number/Issue Date</u>
<b>Bioreductive Cytotoxic Agents</b>	US 09/083,652 Filed May 22, 1998	US 5,969,133 Issued October 19, 1999
<b>Quinone Derivatives</b>	US 09/316,190 Filed May 21, 1999	US 6,433,199 Issued August 13, 2002
<b>Bis(Haloethyl)aminobenzene Derivatives</b>	09/181,436 Filed October 28, 1998	US 6,137,003 Issued October 24, 2000
<b>Cyanoguanidine Compounds</b>	09/545,430 Filed April 7, 2000	US 6,255,323 Issued July 3, 2001
<b>Inhibitor of IL-12 Production</b>	US 09/594,362 Filed June 15, 2000	US 6,384,032 Issued May 7, 2002
<b>Epoxyvibsanin B</b>	US 10/056,699 Filed January 25, 2002	US 6,462,078 Issued October 8, 2002
<b>Taxol Enhancer Compounds</b>	US 60/304,252 Filed July 10, 2001	N/A
<b>Taxol Enhancer Compounds</b>	US 60/361,946 Filed March 6, 2002	N/A
<b>Pyrimidine Compounds</b>	US 10/193,075 Filed July 10, 2002	N/A

B640757.A

<u>Title</u>	<u>US Application Number/Date</u> <u>(IP Counsel Reference No.)</u>	<u>International Application</u> <u>Number/Date</u>	<u>Issued Patent Number/Date,</u> <u>Publication Number/Date and</u> <u>Other Status</u>
<b>Taxol Enhancer Compounds</b>	US 60/361,936 Filed March 6, 2002	N/A	
<b>Taxol Enhancer Compounds</b> (continued)	US 10/193,639 Filed July 10, 2002	N/A	
<b>Synthesis of Taxol Enhancer</b>	US 60/304,318 Filed on July 10, 2001	N/A	
<b>Pyrimidine Compounds</b>	US 10/193,076 Filed July 10, 2002	N/A	
<b>1-Glyoxylamide Indolizines</b> <b>for Treating Cancer</b>	US 60/322,020 Filed Sep. 13, 2001	N/A	
<b>2-Aroylimidazole Compounds</b> <b>for Treating Cancer</b>	US 60/322,105 Filed Sep. 13, 2001	N/A	
<b>3-Glyoxylamide Indolizines</b> <b>for Treating Cancer</b>	US 60/322,022 Filed Sep. 13, 2001	N/A	
<b>Triazine Compounds</b>	US 10/006,624 Filed Nov. 30, 2001	N/A	
<b>Pyrimidine Compounds</b>	US 10/000,742 Filed Nov. 30, 2001	N/A	
<b>Pyrimidine Compounds CIP</b>	US 10/192,347 Filed 7/10/02	N/A	

B640757.4

PATENT

RECORDED: 06/14/2005

REEL: 016142 FRAME: 0854